Trovagene Inc. (TROV) Trading Down 1%
Shares of Trovagene Inc. (NASDAQ:TROV) were down 1% during mid-day trading on Friday . The stock traded as low as $4.88 and last traded at $4.91, with a volume of 111,237 shares traded. The stock had previously closed at $4.96.
Several analysts have issued reports on TROV shares. Maxim Group reissued a “buy” rating on shares of Trovagene in a research note on Monday, June 6th. Cantor Fitzgerald raised shares of Trovagene from a “hold” rating to a “buy” rating and raised their price objective for the stock from $5.00 to $7.00 in a research note on Monday, August 8th. Piper Jaffray Cos. reissued a “hold” rating and issued a $5.00 price objective (down previously from $8.00) on shares of Trovagene in a research note on Thursday, May 12th. Leerink Swann reaffirmed a “hold” rating on shares of Trovagene in a research note on Thursday, May 12th. Finally, Zacks Investment Research raised shares of Trovagene from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Trovagene has a consensus rating of “Hold” and a consensus target price of $7.13.
The company has a 50-day moving average price of $5.30 and a 200 day moving average price of $5.04. The firm’s market capitalization is $149.53 million.
Trovagene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.03. On average, analysts forecast that Trovagene Inc. will post ($1.34) EPS for the current fiscal year.
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.